Background: Treatment for hidradenitis suppurativa is often empiric and inadequate, and determining which patients will respond is difficult.
H idradenitis suppurativa (HS) is a chronic cutaneous condition characterized by recurrent painful nodules, abscesses, scarring, and sinus tract formation. 1 HS is a prevalent but underrecognized health problem, affecting 0.006% to 4.1% of the general population. 2, 3 Patients typically present in their second and third decades of life, with an average age of onset between 20 and 27 years. [4] [5] [6] More women than men are affected by HS, with a female-to-male ratio of approximately 4:1, and the diagnosis of HS is often delayed as a result of misdiagnosis. 5, 7 The pathophysiology of HS is not completely understood, but disease development is most likely related to environmental factors driving disease development in genetically susceptible individuals. 8 Several factorse such as smoking, obesity, insulin resistance, family history, and several autoimmune/ inflammatory diseasesewere repeatedly demonstrated to be associated with HS development. 9, 10 Given that HS development is not fully understood and it is associated with a plethora of factors, any information about which patients with HS will respond to first-line medical therapy and which patients may require therapy escalation could prove highly valuable to clinicians. With this in mind, the goal of this study was to determine which patient factors were associated with a positive response to first-line medical therapy in patients with HS.
METHODS

Study design
All portions of this study were conducted at Washington University School of Medicine as a part of an institutional review boardeapproved study. A retrospective cohort chart review was performed for all patients seen at Washington University School of Medicine affiliate hospitals, namely Barnes Jewish Hospital and St Louis Children's Hospital, between January 1, 1992, and October 1, 2014. Patients were identified through billing records, using the International Classification of Diseases, Ninth Revision code for HS, 705.83.
Inclusion/exclusion criteria
Patients must have had: a dermatologist-confirmed diagnosis of HS, been prescribed only first-line medical therapy at their initial HS-specific dermatology visit, and had a follow-up visit within 6 months of the initial visit. First-line medical therapy was defined as any of the following alone or in any combination: oral antibiotics, topical antibiotics, intralesional corticosteroids, and antibacterial washes/creams/lotions (eg, benzoyl peroxide soap). 11 Patients were included in analysis regardless their compliance to their prescribed medication regime.
Data collection
Patient records were identified in the electronic medical record (EMR), and study data were collected and managed using research electronic data capture tools hosted at Washington University in St Louis. 12 The first HS-specific dermatologist (initial) visit was defined as the earliest note in the EMR where HS symptoms were addressed or treated. Patient demographics were collected from the EMR at the closest possible dates within 61 year of the patient's initial visit. The patient's weight and height were recorded at the closest possible date to the initial visit, and body mass index was calculated from this in the standard fashion.
Patients were considered to have a positive family history of HS if stated explicitly, or to have a noted family history of recurrent boils or abscesseseor similar descriptorein typical HS locations. Patient medical comorbidities were based on all available data recorded in the EMR before the initial visit. Patients were considered to have a positive history of any medical condition if it was noted in the EMR at any point before their initial visit. Any recorded diagnosis of an autoimmune condition, regardless of its association with HS, was noted (please see Fimmel and Zouboulis 13 for a complete listing of HS-associated autoimmune conditions and Hayter and Cook 14 for a comprehensive list of well-described autoimmune diseases). Disease severity was assigned at the initial visit, and was based on the stated physician assessment of disease. When there was no stated physician grading of the patients' disease, the authors assigned a grade based on the Hurley 1 criteria. Those with inactive disease were graded as mild disease, because of the intermittent nature of mild HS. Surgical scars from previous treatments were not included as scarring caused by HS when judging disease severity.
Outcomes
At the first follow-up visit within 6 months of the initial visit patients were dichotomously assigned to either improved or no change/worsening disease. The response to treatment was hierarchically based on either stated improvement at follow-up, or an improvement in the grading of patient disease at the follow-up visit. If the physician recorded a response to treatment at the follow-up visit, it alone was used
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to judge response. However, if no response to treatment was noted in the follow-up note, then the response to treatment was based purely on disease severity/physical examination findings at the follow-up visit compared with the initial visit.
Statistics
Simple descriptive statistics were used to describe the overall study population. Factors selected for logistic regression analysis were based on published literature of factors associated with HS, and clinical expertise. Univariate binary logistic regression was used to examine the association between these patient factors and an improved disease status at the follow-up visit. After this, a multivariate binary logistic regression model was constructed using the same factors. The model was constructed in a single-block, 1-step manner. Model diagnostics were performed by: exploring multicollinearity between factors using a linear regression model and tolerances, examining pseudo r 2 values, and examining a receiver operating characteristic curve and c-statistic. Patients were then stratified on smoking status (current vs non/former), and descriptive statistics were rerun and compared between these groups. Smoking stratification was chosen because of its high prevalence, modifiable nature, and well-known association with HS development and more severe HS. 15 Pearson x 2 test, Fisher exact test, and independent samples t tests were used to compare these groups as appropriate. All statistics were performed using software (SPSS Statistics for Mac, Version 23.0, IBM Corp, Armonk, NY). All figures were made using software (GraphPad Prism, Version 6 for Mac, GraphPad Software, La Jolla, CA).
RESULTS
A total of 945 patients were identified through billing records using International Classification of Diseases, Ninth Revision code 705.83. Of these, 667 (70.6%) were seen by dermatology for HS. Of these 667 patients, 373 (55.9%) were excluded because of no follow-up visit within 6 months and 48 (7.2%) were excluded as a result of either second-line therapies being started or no therapies during their initial visit. The final study population of 246 (36.9%) individuals is described in Table I . The mean age at presentation to our service for HS symptoms was 33.3 (SD 14.8) years, and the median age range of HS symptom onset was between the 16 and 20 years. At presentation, 4 (1.6%) of the patients were unable to be assigned a disease severity. The remaining 242 (98.4%) either had disease severity explicitly noted or had extensive enough physical examination findings recorded to assign a disease severity. At their initial visit, 214 (87.0%) of the patients were prescribed oral antibiotics, 136 (55.3%) were prescribed topical antibiotics, 47 (19.1%) were given intralesional corticosteroids, and 146 (59.3%) were prescribed antimicrobial creams/washes/lotions. At the follow-up visit, 132 (53.7%) of the patients had improvement in their disease. Of note, 46 (18.7%) of patients had some form of noted noncompliance (Table II) . In the multivariate binary logistic regression model, after controlling for all other factors, 2 factors were associated with increased odds of having a positive response to first-line therapy (Table II) . Non/former smokers were at a 2.634 (95% CI 1.301-5.332, P = .007) times increased odds of having improvement in their disease compared with current smokers, regardless of the amount smoked. In addition, each 1-year increase in age at the initial HS-specific visit saw a 4.6% (95% CI 1.020-1.072, P \ .001) increase in the odds of having improved disease at the follow-up visit. Although no longer statistically significant in the multivariate model, there was a nearly significant association between improvement at follow-up and no previous diagnosis of HS (OR 1.905, 95% CI 0.958-3.790, P = .066). In the final binary logistic regression model, 198 (80.5%) of the 246 patients had all of the necessary information to be included. The overall multivariate model was statistically significant (P = .020), with no multicollinearity noted between any of the variables.
When stratified on smoking status, current smokers did differ significantly from non/former smokers in several regards (Table III) . Current smokers were significantly older at their initial visit, with a mean age of 38.9 years, compared with non/former smokers, with a mean age of 29.6 years (P \ .001). Current smokers were more likely to be Caucasian (OR 2.41, 95% CI 1.427-4.069, P = .001), less likely to have a recorded family history of HS or HS-like syndrome (OR 0.341, 95% CI 0.134-0.867, P = .019), more likely to have a history of an autoimmune condition (OR 3.127, 95% CI 1.601-6.108, P = .001), and more likely to have inframammary HS involvement (OR 3.132, 95% CI 1.460-6.715, P = .002).
DISCUSSION
The factors we identified as significantly associated with a positive response to medical treatment align with much of what is currently known about HS. It is estimated that the rate of active current smoking in patients with HS is 40% to 88.9%, with current smokers having worse disease than those who do not smoke. [15] [16] [17] Smoking is known to be associated with derangement of inflammatory cell lines and cytokines, and if HS development is indeed related to a dysregulated inflammatory state, then it stands to reason that current smokers may be less likely to respond to medical therapy. 8, 18 In regards to age at presentation playing a strong role in response to therapy, it may be related to either the possible autoimmune/ autoinflammatory nature of HS or to hormonal factors. If HS is indeed being driven by an autoimmune/autoinflammatory component in some patients, then it is possible that they will have more mild disease if they develop HS later in life, similar to how many autoimmune conditions have a better prognosis as age of onset increases. 19 In addition, the decreasing levels of androgens found as an individual ages may influence HS responsiveness to treatment. There is some evidence that either high androgen levels and/or tissue sensitivity to androgens is important in HS development, and because of this, antiandrogen therapy may be used in treating HS. [20] [21] [22] If androgens truly play an important role in HS pathogenesis, then the decreasing levels of these hormones seen as individuals age could explain why HS is more amenable to treatment in older patients in this study. 23 Lastly, it stands to reason that not having a previous diagnosis of HS was associatedealthough only statistically significant in the univariate modelewith a positive response to treatment because these individuals are likely earlier in their disease course compared with those who came for treatment with a diagnosis already established.
Limitations of this study stem predominately from its retrospective nature. Missing data limited the number of patients who could be included in the multivariate binary logistic regression model. The majority of patients who were not included in the final model were missing sufficient information to calculate a body mass index (44 of the 48 not included in the final model). However, 198 (80.5%) of the eligible population had all of the data necessary for inclusion in the final model. In addition, misclassification of disease severity was a serious concern, as some patients could only be classified based on noted physical examination findings. However, the distribution of disease severity seen in this study population closely matches previously described distributions. 24 Lastly, these results may not be generalizable, as they are derived from a single academic tertiary-care center over a short time course. Regardless of these limitations, these findingseparticularly the strong association with smoking statuseare clinically meaningful.
In conclusion, older age and being a current nonsmoker were both factors associated with a positive response when initializing treatment with oral antibiotics, topical antibiotics, intralesional corticosteroids, or antibacterial washes/creams/ lotions. Cigarette smokingethe only modifiable factor identifiedeis highly important clinically, as patients should be advised that quitting smoking may improve their response to treatment and decrease the likelihood of inframammary HS involvement. Further studies, particularly looking at multiple centers over a much longer time course, are needed to ensure the generalizability of these results.
